Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical DNA repair enzyme in the base
excision repair pathway. Inhibitors of this enzyme comprise a new type of anticancer drug …

Cancer is a societal burden demanding innovative approaches. A major problem with the
conventional chemotherapeutic agents is their strong toxicity and other side effects due to …

Background: Clinical response to chemotherapy for ovarian cancer is frequently
compromised by the development of drug-resistant disease. The underlying molecular …

The materials community has witnessed a complexity expansion in semiconducting
polymers by structural engineering. The most thriving area of polymeric semiconductors lies …

One of the major challenges confronting organic electronics is the development of high-
mobility semiconducting materials, especially n-channel and ambipolar semiconductors …

Poly (ADP-ribose) polymerase-1 (PARP-1) is a new potential target for anticancer drug
discovery. A series of bromophenol–thiosemicarbazone hybrids as PARP-1 inhibitors were …

Azaindole structural framework is an integral part of several biologically active natural and
synthetic organic molecules; and several FDA approved drugs for various diseases. In the …

Olaparib was the first PARP inhibitor approved by the FDA for patients with BRCA-mutated
ovarian cancer. Recent studies have demonstrated enhanced anticancer effects of …

The azaindole chemical scaffold is represented in many biologically active natural products
and synthetic derivatives. Recently, this chemical scaffold yielded several therapeutic agents …

In this study, new dibenzensulfonamides, 7–9, having the chemical structure 4, 4′-(5′-
chloro-3′-methyl-5-aryl-3, 4-dihydro-1′ H, H-[3, 4′-bipyrazole]-1′, 2-diyl) …